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ABSTRACT
Objectives This review provides insights into the potential 
for aspirin to preserve bone mineral density (BMD) and 
reduce fracture risk, building knowledge of the risk- benefit 
profile of aspirin.
Methods We conducted a systematic review and 
exploratory meta- analysis of observational studies. 
Electronic searches of MEDLINE and Embase, and a 
manual search of bibliographies was undertaken for 
studies published to 28 March 2018. Studies were 
included if: participants were men or women aged ≥18 
years; the exposure of interest was aspirin; and relative 
risks, ORs and 95% CIs for the risk of fracture or difference 
(percentage or absolute) in BMD (measured by dual energy 
X- ray absorptiometry) between aspirin users and non- 
users were presented. Risk of bias was assessed using 
the Joanna Briggs Institute Critical Appraisal Checklists 
for observational studies. Pooled ORs for any fracture and 
standardised mean differences (SMDs) for BMD outcomes 
were calculated using random- effects models.
Results Twelve studies met the inclusion criteria and 
were included in the meta- analysis. Aspirin use was 
associated with a 17% lower odds for any fracture 
(OR 0.83, 95% CI 0.70 to 0.99; I2=71%; six studies; 
n=511 390). Aspirin was associated with a higher total hip 
BMD for women (SMD 0.03, 95% CI −0.02 to 0.07; I2=0%; 
three studies; n=9686) and men (SMD 0.06, 95% CI −0.02 
to 0.13, I2=0%; two studies; n=4137) although these 
associations were not significant. Similar results were 
observed for lumbar spine BMD in women (SMD 0.03, 
95% CI −0.03 to 0.09; I2=34%; four studies; n=11 330) 
and men (SMD 0.08; 95% CI −0.01 to 0.18; one study; 
n=432).
Conclusions While the benefits of reduced fracture risk 
and higher BMD from aspirin use may be modest for 
individuals, if confirmed in prospective controlled trials, 
they may confer a large population benefit given the 
common use of aspirin in older people.
InTROduCTIOn
The anti- inflammatory effects of aspirin via 
prostaglandin inhibition have recently gained 
attention. Chronic low- grade inflammation 
contributes to age- related cardiovascular, 
neurological, respiratory and musculoskel-
etal conditions.1 Low- grade inflammation 
is associated with increased bone loss and 
fracture risk.2 3 Prostaglandin, an important 
inflammatory mediator, is likely to have a 
key role in bone remodelling attributable 
to inflammation.4 Prostaglandin E2 stimu-
lates bone resorption and formation and 
is produced largely from cyclooxygenase-2 
induction. Prostaglandins acutely inhibit 
osteoclast function.5 However, their chronic 
effect is to stimulate bone resorption by 
increasing replication of osteoclast precur-
sors, and differentiation to mature osteo-
clasts. Aspirin is an inhibitor of prostaglandin 
production and may influence the cellular 
basis of bone remodelling responsible for 
maintaining the material and structural 
strength of bone.1
These findings have led to growing interest 
in the potential for aspirin treatment to 
provide health benefits broader than cardio-
vascular, particularly in the prevention of 
age- related conditions. Osteoporosis—low 
bone mineral density (BMD) and structural 
deterioration of bone leading to increased 
risk of fractures—is the most common bone 
disease.6 More than 8.9 million fractures 
occur annually—equivalent to one fracture 
Strengths and limitations of this study
 ► This systematic review extends prior observational 
studies by providing new evidence that suggests as-
pirin may be associated with reduced fracture risk 
and potentially higher bone mineral density.
 ► üThe observational studies included in this system-
atic review demonstrate an association between 
fracture risk and exposure to aspirin but firm con-
clusions about causation cannot be inferred without 
prospective controlled trials.
 ► üEven a small reduction in fracture risk forindividu-
als is likely to translate to large benefits at a popu-
lation level given the common use of aspirin in older 
people most at risk of fractures.
2 Barker AL, et al. BMJ Open 2020;10:e026876. doi:10.1136/bmjopen-2018-026876
Open access 
every 3 s.7 The combined lifetime risk for hip, forearm 
and vertebral fractures requiring medical attention is 
around 40%—equivalent to the risk for cardiovascular 
disease.8 Despite the availability of several therapies, oste-
oporosis remains underdiagnosed and undertreated.9 Up 
to 80% of those with at least one osteoporotic fracture do 
not receive treatment.9 As the ageing population grows 
worldwide, including in countries with under- resourced 
health systems,10–12 so will the demand for therapies that 
are low- cost, safe and readily available.13 If aspirin use 
reduces the risk of fracture, the public health impacts may 
be considerable because even a small benefit in averting 
or reducing age- related bone fragility may have a large 
impact at the community level.
There have been no randomised controlled trials 
(RCTs) reporting on the effects of aspirin treatment 
and fracture risk in human subjects. While there are 
increasing numbers of observational studies, findings are 
contradictory regarding associations between aspirin use 
and BMD14–17 and fracture risk.15 18–26 A review by Chin,27 
concluded that aspirin may increase BMD, but its effect 
on fracture prevention is inconclusive. The limitations of 
this review were that it included only five observational 
studies and did not pool quantitative data via meta- 
analysis or other methods.
Purpose of the current review
Fractures are a growing personal and financial burden 
to individuals and the healthcare system.7 While there is 
some indication that aspirin use may be associated with 
improved BMD and reduced fracture risk, a meta- analysis 
would yield further insights. Conducting a meta- analysis 
where data are pooled across several studies can provide 
an opportunity to identify associations that may have gone 
undetected in individual studies. The aim of this system-
atic review was to resolve the controversy in findings from 
prior studies by conducting an exploratory meta- analysis 
to examine associations between aspirin use and fracture 
risk and BMD in adults.28
MATeRIAlS And MeThOdS
Search strategy and selection criteria
We undertook a systematic review and meta- analysis 
in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses guidelines. An 
electronic search for all literature (database inception 
to 28 March 2018) was performed using Ovid Medline 
and Embase. The search used MeSH terms (‘aspirin’ 
OR ‘acetylsalicylic acid’ OR ‘paracetamol’ OR ‘non- 
steroidal anti- inflammatory drugs’) AND (‘fracture’ 
OR ‘bone mineral density’ OR ‘osteoporosis’). In addi-
tion, a manual search of cited references from retrieved 
studies, recent systematic reviews, and meta- analyses was 
conducted (refer online supplementary material 1 for the 
list of search terms).
Two authors (JT and Sze- EeSoh) screened titles and 
abstracts to identify potentially relevant studies, and if a 
decision could not be made, the full text of the article 
was examined. Full length articles of selected abstracts 
were retrieved and assessed independently by two authors 
(JT and ALB). Studies were considered eligible for the 
meta- analysis if: (1) participants were men or women 
aged 18 years or older; (2) the exposure of interest was 
aspirin; and (3) relative risks, HR or OR and 95% CIs for 
the risk of fracture or difference (percentage or abso-
lute) in BMD (measured by dual energy X- ray absorpti-
ometry (DXA)) between aspirin users and non- users were 
presented, or sufficient data were provided to enable 
these values to be calculated. We included studies that 
reported aspirin dose and duration either via self- report 
or identified through prescription histories. Studies were 
also included if an identifiable and separately analysed 
subgroup of people using aspirin was presented. Fracture 
outcomes included the number or rate of any fractures 
including non- vertebral fractures verified by imaging, 
while BMD outcomes included measures of bone mass of 
the whole body as well as at the total hip, proximal femur, 
femoral neck and spine or lumbar regions. When more 
than one article presented data from the same study 
population, the article with more complete reporting of 
data was selected to avoid double counting participants in 
the meta- analysis.29
Our aim was to include as many studies as possible 
in our meta- analysis, considering the limited number 
of published studies. Any study design was accepted 
including RCTs, other than single case design studies 
and systematic reviews. Grey literature such as PhD theses 
and conference abstracts were excluded to allow a repro-
ducible search strategy. Only papers in English were 
considered.
Assessment of risk of bias
The risk of bias of included studies was assessed inde-
pendently by two authors (JT and SES) using the suite 
of Joanna Briggs Institute (JBI) Critical Appraisal Check-
lists which have been approved by the JBI Scientific 
Committee following extensive peer review.30 31 The JBI 
critical appraisal tools are designed to assess the extent 
to which a study has addressed the possibility of bias 
in its design, conduct and analysis.30 These checklists 
assessed the sample characteristics, ascertainment of 
exposure, presence of confounding factors, measure-
ment of outcomes, and the use of appropriate statistical 
techniques. Different criteria were used to appraise meth-
odological quality depending on the study design to mini-
mise bias and improve reliability of findings.32
For cohort studies, the criteria assessed whether groups 
were similar, if the follow- up time was sufficient to allow 
outcomes to occur, and loss to follow- up. For case- control 
studies, the criteria addressed issues related to the defini-
tion of cases and controls, selection of control and repre-
sentativeness of cases, and the comparability of cases and 
controls. In cross- sectional studies, there was a focus on 
whether the inclusion criteria and setting of the study 
were clearly defined. Discrepancies in extracted data and 
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quality appraisal were discussed and cross- referenced 
to the original article using a priori decision rules. If 
consensus could not be gained, agreement was obtained 
through discussions with a third person (ALB) as per 
the method described in the Cochrane Handbook for 
Systematic Reviews of Interventions.33
data extraction
Data from included studies were independently extracted 
by two authors (JT and SES) using a customised elec-
tronic data extraction form that was piloted with a 
number of representative studies to ensure the content 
was appropriate. We extracted information from each 
study on first author; year and country of study; partic-
ipant numbers and characteristics; study design; aspirin 
dose and duration; number of fractures (including site 
where available); BMD measures for each site (eg, whole 
body, proximal femur, total hip, femoral neck or lumbar 
spine); duration of follow- up; and covariates included for 
adjustment in the analysis.
Statistical analysis
In order to include studies with more than one treatment 
arm (eg, different aspirin doses) but only one control 
group, the effect estimate reported for each treatment 
group was included separately within the meta- analysis. 
However, the number of participants in the control group 
were divided equally between the comparisons as per the 
method described in the Cochrane Handbook for System-
atic Review of Interventions.33 This process ensured that 
control participants were not counted more than once 
within the meta- analysis.33
Because of the various ways in which the authors 
reported data on changes in BMD and also wanting to 
maximise the number of studies and outcomes that could 
be included in our analysis, we used the standardised 
mean difference (SMD) approach33 as our summary 
statistic as opposed to the mean difference (MD) 
approach. The SMD yields a more conservative estimate 
than the MD, however, this was considered appropriate 
given the broad inclusion criteria of this review (which is 
likely to yield heterogeneity) and exploratory nature of 
the analysis where we wanted to minimise the likelihood 
of a type I error (false positive result). This approach 
allowed a direct comparison of associations across trials 
that reported either absolute or relative changes in BMD. 
For each study, the SMD was calculated as follows:
 
SMD =
meanaspirin−meannon−aspirin
SDpooled
(
1− 3
4
(
Ntotal
)−9
)
 
(1)
The MD between aspirin and non- aspirin users was 
divided by the SD of the difference in BMD for all partici-
pants pooled across both treatment groups, and adjusted 
for small sample bias.34 The SE for the SMD was then 
calculated using the following formula:
 
SE
{
SMD
}
=
√
Ntotal(
naspirin
)(
nnon−aspirin
) + SMD2
2
(
Ntotal−3.94
)
 
(2)
If studies lacked SD estimates but provided a SE or 
CI that related to the MD, we estimated SDs using the 
following methods33:
1. From SE to SD: the following formula was used: 
 SD = SE ×
√
N .
2. From 95% CI to SE:  SE =
(
upper limit−lower limit)
3.92  .
The OR and 95% CI (if available) was used to describe 
the association between aspirin use and fracture risk. 
Effect estimates were manually calculated when needed. 
Unless otherwise stated, we used the most adjusted risk 
estimate from each study.
It is known that results may vary systematically with 
observational study designs.35 As such, for each meta- 
analysis we performed a subgroup analysis based on study 
design to explore this. If no significant subgroup differ-
ences were identified, study designs were pooled in one- 
meta- analysis. The meta- analysis included subgroupings 
for aspirin doses (low dose (≤150 mg/day), high dose 
(>150 mg/day) and not reported) and sex in relation 
to fracture risk and BMD. As sex is an important effect 
modifier of BMD, results were reported separately for 
men and women. Sensitivity analyses were also performed 
by removing each individual study from the fracture and 
BMD meta- analysis, and removing studies based on study 
design to assess the robustness of our findings.
Additionally, the effect of aspirin on BMD or fracture 
risk was examined only when at least five studies reported 
on the outcome in order to ensure that we had sufficient 
power to detect a difference between the groups.36 We 
assessed heterogeneity between studies with the I2 statistic 
as a measure of the proportion of total variation in esti-
mates that is due to heterogeneity. As heterogeneity was 
suspected in the data due to different study designs, study 
populations, follow- up duration and aspirin dose and 
duration, a random effects model was used. If the I2 value 
exceed 75% then a meta- analysis was not undertaken.37 
An inverse variance method was also used to weight each 
estimate. All analyses were conducted with the use of 
Review Manager, V.5.0 (Revman, The Cochrane Collab-
oration; Oxford, UK) which allowed estimates and their 
SE to be entered directly using the ‘Generic Inverse Vari-
ance’ outcome to facilitate the analysis of continuous 
and dichotomous outcome data from non- randomised 
studies.33 38
Patient and public involvement
There was no direct patient or public involvement in this 
review.
ReSulTS
description of studies
There were 655 articles identified, 12 were duplicates 
and 601 were excluded after reviewing the titles and 
abstracts, leaving 46 articles. An additional four arti-
cles were found from reviewing references from articles 
obtained in full text. After full text review, a total of 14 
articles were assessed as eligible for inclusion. However, 
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- Analyses flowchart of study selection process.
only 12 studies were used as three19 21 26 reported different 
outcomes on the same sample (figure 1). To avoid double 
counting, only data from Vestergaard et al26 was used 
for the meta- analysis as it reported the most complete 
dataset. Of the 12 unique studies, three were prospective 
cohort studies,15 18 22 three were case- control studies,20 25 26 
and six were cross- sectional studies14 16 17 23 24 39 (table 1). 
Four studies reported fracture outcomes only,18 20 25 26 six 
studies reported BMD outcomes only14 16 17 23 24 39 and the 
remaining four studies reported both fracture and BMD 
outcomes15 22 (online supplementary materials 1 and 
2). We were unable to identify any RCTs of aspirin that 
included data on fracture or BMD outcomes.
Risk of bias in included studies
The risk of bias assessment is reported in table 2. The risk 
of bias was considered low for the three cohort studies 
with respect to the exposure, identifying and dealing 
with confounders, measuring outcomes, having sufficient 
follow- up time and using appropriate statistical analysis. 
Measurement of fracture and BMD outcomes were consid-
ered reliable and valid. Fractures were verified using 
radiological reports or obtained using the International 
Classification of Diseases 10 codes (online supplementary 
material 2), while all BMD outcomes were measured using 
DXA scans (online supplementary material 3). In contrast, 
reasons for loss of follow- up were not well documented, 
with only one18 describing strategies to address incomplete 
follow- up. For the case- control studies, the risk of bias was 
low for most studies19 21 25 26 except for one20 which did not 
provide sufficient information regarding the cases and 
controls, as well as how exposure to aspirin was measured. 
The risk of bias for identifying confounders, measuring 
outcomes and using appropriate statistical analysis was low 
for all cross- sectional studies. However, inclusion criteria, 
study subjects, and measurement of exposure were poorly 
defined in a number of studies.14 16 23 39
Meta-analysis
Effect estimates (ie, ORs) for the association between 
aspirin use and fracture risk were manually calculated for 
two studies.20 25 The MD in BMD outcomes were reported 
by three studies,22 24 39 with the remaining studies reporting 
percentage difference in BMD.14–17 23 Using equations (1) 
and (2), the SMD and SE for the SMD was calculated for 
each study and used in the meta- analysis.
No significant differences were identified when we 
performed a subgroup analysis based on study design 
(figure 2). Thus, data from included studies were pooled 
into one meta- analysis for fracture and BMD outcomes. 
Data pooled from six studies that included 511 390 
people indicated aspirin was associated with a 17% lower 
odds of any fracture (OR 0.83, 95% CI 0.70 to 0.99; 
I2=70%; figure 3). There was no significant difference in 
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Figure 2 Meta- analysis of the association by study design of the association between aspirin use and (A) risk of any fracture 
(adjusted OR); (B) hip bone mineral density; and (C) lumbar spine bone mineral density.
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Figure 3 Meta- analysis of the association between aspirin use and risk of any fracture (adjusted OR) by aspirin dosage.
associations across dose subgroups (figure 3). A subgroup 
analysis on studies that included only women was not 
undertaken as considerable heterogeneity was observed 
with an I2 value of 78%. There were no studies that exam-
ined risk of fractures only in men.
Aspirin was associated with a higher total hip BMD for 
women (SMD 0.03, 95% CI −0.02 to 0.07; I2=0%; three 
studies; n=9686; figure 4A) and men (SMD 0.06, 95% CI 
−0.02 to 0.13, I2=0%; two studies; n=4137; figure 4A) 
although these associations were not significant. There 
were also no significant differences in associations across 
dose (figure 4B). Similar results were observed for lumbar 
spine BMD in women (SMD 0.03, 95% CI −0.03 to 0.09; 
I2=34%; four studies; n=11 330; figure 4C) and men (SMD 
0.08, 95% CI −0.01 to 0.18; one study; n=432; figure 4C).
Sensitivity analysis was performed whereby each study 
was removed from the fracture and BMD meta- analysis. 
The direction of association remained when individual 
studies were removed but significance often changed. For 
example, when the Williams et al20 study was removed from 
the analysis, aspirin was associated with a 7% lower odds 
of any fracture (OR 0.93, 95% CI 0.91 to 0.95). When we 
removed the Bauer et al15 study from the lumbar spine 
BMD meta- analysis, aspirin use was associated with higher 
spine BMD in women (SMD 0.04, 95% CI −0.10 to 0.17) 
and men (SMD 0.08, 95% CI −0.01 to 0.18). Similar results 
were obtained when we removed individual studies based 
on type of design.
No meta- analyses were undertaken for femoral neck 
or total body BMD as there were too few studies. Only 
four studies reported on femoral neck BMD16 17 22 23 
and two reported on total body BMD with conflicting 
results.14 22 Two studies reported no association between 
aspirin and femoral neck BMD,22 23 while two reported 
a higher femoral neck BMD in aspirin users compared 
with non- users.16 17 Likewise, only one of the studies that 
reported on total body BMD reported a higher total BMD 
in aspirin users compared with non- users.14
dISCuSSIOn
Main findings
Aspirin is one of the most commonly used medica-
tions worldwide and has the potential to benefit and/
or prevent many chronic diseases. This review extends 
previous reviews of aspirin and bone27 by including 
additional studies16–18 20 23–25 40 and an exploratory meta- 
analysis. While firm conclusions about causation cannot 
be inferred, and nor was this the intent of our exploratory 
review, our findings suggest that aspirin use was associated 
with a lower risk of any fracture and potentially higher 
BMD at the spine and hip. These findings are consistent 
with preclinical and animal studies.27 While the reduction 
in fracture risk was small, given the widespread use of 
aspirin and the high prevalence of undetected low bone 
density, even small reductions in fracture risk may yield 
considerable benefits at a population level. Even though 
we do not expect that aspirin would be considered as a 
primary fracture prevention therapy, this study builds on 
the knowledge of the potential broader benefits of aspirin 
therapy for those taking it for cardiovascular indications.
The consistent findings of reduced risk of fracture 
across studies included in this review is encouraging. It is 
important to keep in mind that studies were quite diverse in 
design, populations included, data collection methods and 
follow- up periods and we did observe high heterogeneity 
especially for fracture risk. While we need to interpret this 
finding with some caution, there appeared to be a consis-
tent indication that aspirin use is associated with positive 
bone outcomes. While our findings suggest that dose and 
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Figure 4 Meta- analysis of the association between aspirin use and bone mineral density in the (A) hip by sex; (B) hip by aspirin 
dosage; (C) lumbar spine by sex; and (D) lumbar spine by aspirin dosage.
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sex subgroups do not influence bone outcomes, these 
subgroup analyses were likely underpowered. Only eight 
of the 14 publications reported aspirin dosage in terms 
of frequency and dose. There were also no studies that 
reported on aspirin use and fracture outcomes in men only. 
In contrast, six of the studies were conducted in women 
only.15 17 18 20 22 39 Future studies should aim to collect and 
report findings for different aspirin doses and sex to enable 
dose- and- or sex related effects (if any) to be ascertained.
When low- dose aspirin use is recommended for preven-
tion of cardiovascular disease by a healthcare professional, 
nine of 10 adults will follow the recommendation.41 This 
suggests the drug is broadly accepted by patients as a treat-
ment regime. The findings of this review build on the 
existing evidence that supports the role of aspirin in the 
prevention of conditions including cancer42 and depres-
sion.43 As the population ages, increasing numbers of older 
people will be taking aspirin. Knowledge of the relative 
benefits and risks beyond cardiovascular in older individ-
uals is critical to inform treatment decisions. If future RCTs 
provide evidence of positive effects on bone and fracture 
prevention, it will be reassuring for those taking aspirin for 
cardiovascular indications to know that the drug has addi-
tional positive health impacts beyond those for which its 
primary therapeutic effect was intended.
limitations
Some caution is needed in interpreting the findings. 
The search strategy included full- text reports published 
in English and we may have missed studies in other 
languages. In addition, meta- analyses of observational 
studies are subject to the same biases and confounding 
in the original studies such as confounding by indica-
tion and unmeasured factors, self- report of aspirin use, 
and survival bias. We minimised these limitations by: 
(1) developing explicit and broad criteria that focused 
on extracting the best available evidence44 45; (2) util-
ising a broad search strategy to ensure that all relevant 
literature was included45; and (3) exploring sources of 
heterogeneity by conducting subgroup analyses, none 
of which revealed any significant differences in find-
ings. Importantly, several studies reported aspirin users 
and non- users differed at baseline in risk factors for 
fracture. These included: age15; sex14; race14; weight15 40; 
oestrogen therapy14 15; prescription of medications known 
to increase falls risk19 21 26; higher levels of comor-
bidity19 21 26; number of prior fractures19 21 26; and existing 
diagnosis of osteoporosis, osteoarthritis or rheumatoid 
arthritis.14 15 40 While analyses often adjusted for these 
factors, the risk that groups were systematically different 
in factors neither measured nor adjusted for, remains 
high. For example, no study reported adjustment for 
physical activity. Aspirin use could also be a marker for 
an unmeasured confounder. This confounding by indi-
cation, and resulting imbalance in the underlying risk 
profile between aspirin users and non- users, may have 
biassed results. Further, data on confounding variables 
were often self- reported.15 Most studies were subject to 
recall bias particularly with respect to use of aspirin. All 
studies relied on participant self- reporting of current and 
prior aspirin use over long periods of time (range, 1–10 
years), which is known to over- estimate actual drug use,46 
with two studies being completed retrospectively. This is 
likely to increase the potential effect of aspirin on frac-
ture risk and BMD. Finally, none of the studies reported 
fracture or BMD results separately for first or subsequent 
fractures. The cause of fractures (eg, trauma) were also 
not reported by included studies. As such, we are unable 
to determine whether the potential protective association 
of aspirin is for primary or secondary prevention. This 
would be valuable to explore in future research.
Implications
The WHO has identified fracture prevention as a public 
health priority.47 By the year 2040, the number of 
people at high risk of sustaining a fracture will double 
to 319 million.48 The evidence presented in this review 
provides a window into the potential for aspirin to be a 
novel therapy for fracture prevention. While causation 
cannot be inferred from our review findings, we have 
provided a basis to inform future research including 
RCTs that aim to examine the effect of aspirin on fracture 
risk. Given that aspirin use is not without risk any poten-
tial skeletal benefits must be considered in the broader 
context of therapeutic risk. Studies in older people report 
long- term use of aspirin is associated with increased risk 
of major bleeding49 50 including haemorrhagic stroke.51 
Currently there is an absence of RCT data in those aged 
70 years and older who have an increased susceptibility to 
adverse drug effects due to impaired hepatic and renal 
function, polypharmacy and comorbidity. Thus, there 
is a need for future research, particularly RCTs in older 
people to focus on assessing data on multiple end- points 
(such as cardiovascular, bleeding, fractures and mortality) 
in the one population to provide accurate estimates of 
the relative benefits and risks of using aspirin.
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